Keith Tietjen
New York, Ny Usa
A seasoned financial executive with over a decade of experience, Keith Tietjen is currently engaged in operational and restructuring activities at Cerberus Capital Management, L.P., a leading private equity company based in New York City. Prior to joining Cerberus Capital Management, Keith Tietjen was a vice president at General Electric Consumer Finance – Americas.
<br/>
<br/>In 2003 and 2004, Keith Tietjen was VP Finance – Financial Planning & Analysis / CEO Analyst at GE. Keith worked with the firm’s senior business team to meet net income targets and other company goals. Keith Tietjen played an important role in helping the business achieve 20 percent year-over-year growth during his tenure, and the business met all targets and operational metrics for eight consecutive quarters. Additionally, Keith Tietjen helped develop a long-range business strategy that resulted in a plan to deliver 30 percent net income growth and an increase the asset base to over $100 billion.
<br/>
<br/>In 2005, Keith Tietjen accepted the position of Vice President of Finance – Risk, Marketing, Collections & Decision Sciences. In this role, Keith Tietjen helped drive a record low business-wide loss rate of 5.1%. Keith Tietjen also managed $500 million in functional expenses, drove focus on and increased customer-level profitability, acquired and developed talent, and oversaw all planning cycles for risk, collections, marketing, and decision sciences.
<br/>
<br/>Keith Tietjen joined Cerberus Capital Management in April 2006, working with numerous operational projects. In 2007 and 2008, Keith was primarily focused on GMAC ResCap, an industry leading mortgage company. Keith Tietjen led the restructuring of the company and numerous operational improvements. Keith drove over a billion dollars of savings in ResCap.
<br/>
<br/>A resident of New Jersey, Keith Tietjen enjoys a variety of sports in his free time. Keith Tietjen also contributes to a number of charities that help fund research in autism, leukemia, and breast cancer.